Convatec Placental-Derived Device Cleared for Difficult Wound Management

Convatec has received FDA clearance for its InnovaMatrix PD, the first particulate placental extracellular matrix medical device designed for management of complex surgical wounds, chronic stalled wounds and burns.

The device is intended to treat a wide variety of wounds, from surgical and traumatic wounds to burns and diabetic foot ulcers.

The device is a placental-derived xenograft and “has been controlled for genetic variability and environmental and lifestyle factors, such as diet and activity levels,” the company said.

The product doesn’t require preparation or special storage, according to Convatec.